Atria Research and Global Health Institute (ARGHI)
The purpose of this study is to evaluate blood-based measures of organ-specific biological age, with a particular focus on the brain, and to investigate their relationship with established clinical indicators of health and their response to treatment with tirzepatide.
Inclusion Criteria: * Stable medical status (neurological, cardiovascular, and immuno inflammatory) * Adults age 50-75 years * Eligible and waitlisted for brain health program onboarding * Willingness to undergo serial blood sampling, wearable monitoring, and MRI * Willingness to be assigned to the interventional trial or non-interventional trial * Willingness to accept tirzepatide treatment (interventional arm) Exclusion Criteria: * Major neurodegenerative disease (e.g., dementia) * Clinical and correlative imaging history of ischemic or hemorrhagic stroke * History of myocardial infarctio…
Tirzepatide, a dual GLP-1/GIP receptor agonist, is administered by subcutaneous injection once weekly for 6 months. The starting dose is 2.5 mg weekly, with optional dose escalation in 2.5 mg increments at intervals of at least 4 weeks, based on tolerability and investigator assessment, to a maximum of 10 mg weekly.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.